ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 9

Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

, , ,

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
EP. 4: Examining 3-Year Update Data from the CASPIAN Trial
EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC
EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial
EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
Now Viewing
EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
EP. 12: Examining Key Data from DAREON-8
EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Video content above is prompted by the following questions:

  • After frontline therapy in limited-stage small cell lung cancer (LS-SCLC), how do you determine the appropriate second-line and subsequent therapy?
    • What patient-specific factors do you consider?
    • Other than clinical trial enrollment, what would you consider for second-line treatment?
    • Please briefly describe the SWOG umbrella protocol for ES-SCLC
  • Can we personalize treatment by identifying molecular subtypes that may be more responsive to certain therapies than others?
  • Please provide your insights on the potential for improved survival benefits with chemoimmunotherapy and consolidative thoracic radiotherapy in patients with ES-SCLC.
    • What additional research should be conducted to further validate the use of CIT and cTRT in this patient population?
  • Please briefly comment on key updates in SCLC recently presented at ASCO 2024 and discuss how these findings may impact the overall treatment landscape.